Novel Chemotherapeutic Agent FX-9 Activates NF-κB Signaling and Induces G1 Phase Arrest by Activating CDKN1A in a Human Prostate Cancer Cell Line

Investigators conducted microarray gene expression analysis and compared FX-9 exposed and unexposed prostate cancer cells, followed by pathway analysis and gene annotation to functional processes.